Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients

Abstract

Background: A novel gammaretrovirus named xenotropic murine leukemia virus-related virus (XMRV) has been recently identified and found to have a prevalence of 40% in prostate tumor samples from American patients carrying a homozygous R462Q mutation in the RNaseL gene. This mutation impairs the function of the innate antiviral type I interferon pathway and is a known susceptibility factor for prostate cancer. Here, we attempt to measure the prevalence of XMRV in prostate cancer cases in Germany and determine whether an analogous association with the R462Q polymorphism exists.

No Detection of Xenotropic Murine Leukemia Virus-Related Viruses in Prostate Cancer in Sanandaj, West of Iran

“…Herein, we did not detected XMRV and related MLVs DNA in 163 samples of prostate cancer and BPH, which is in consistence with other reports from the USA, Europe, central Africa, China, and Australia Rezaei et al, 2013;Williams et al, 2013). The reasons for this variation in results might be factors such as, geographic distribution, genetic variations of the virus (Hohn et al, 2009;Luczkowiak et al, 2012) and absence of XMRV and related MLVs in human infections. It is also possible that the quality of the specimens were low due to preservation, handling, and the duration of storage prior to DNA isolation.…”

“…In conclusions, several studies have used primers that simultaneously detect XMRV and related MLVs in prostate cancers (Hohn et al, 2009;Aloia et al, 2010;Robinson et al, 2011;Switzer et al, 2011;Das Gupta et al, 2012;Rezaei et al, 2013). But, XMRV or related gamaretroviruses (MLVs) were not detected in our samples.…”

“…But, in Europe (Fischer et al, 2008;Hohn et al, 2009;Verhaegh et al, 2011), the USA, and recent study in Australia detection of XMRV in prostate (Aloia et al, 2010;Switzer et al, 2010;Rezaei et al, 2013), and breast cancer tissues (Khan et al, 2012) have been failed. Herein, we did not detected XMRV and related MLVs DNA in 163 samples of prostate cancer and BPH, which is in consistence with other reports from the USA, Europe, central Africa, China, and Australia Rezaei et al, 2013;Williams et al, 2013).…”

“…Recently a study reported that, XMRV was detectable in some patients with prostate cancer in Kerman, southeast of Iran (Reza et al, 2012). In contrast, in other studies have been found very low or no XMRV prevalence in prostate cancers in Europe (Germany, and the Netherlands) and USA using only RT-PCR (Fischer et al, 2008;Hohn et al, 2009;Aloia et al, 2010;Silverman et al, 2010;Sakuma et al, 2011;Sfanos, 2011;Stieler et al, 2011). Moreover other findings imply that XMRV does not present in humans, and is only seen in the laboratory contamination (Sfanos et al, 2012).…”

XMRV ist nicht human-pathogen und hat keine Bedeutung für die Sicherheit von Blut und Blutprodukten

“…Einzelne Arbeitsgruppen beschrieben ebenfalls XMRV sowohl in Prostatatumoren als auch in anderen klinischen Materialien, darunter waren auch Arbeiten aus Deutschland [6,7]. In der Mehrzahl der später veröffentlich-ten Studien wurde XMRV jedoch in keiner einzigen Probe nachgewiesen [8,9,10,11,12,13]. Bei Wiederholungsuntersuchungen von zuvor am WPI im Rahmen der initialen Studie [3] positiv getesteten CFS-Patienten konnten in unabhängigen Laboren in keinem einzigen Fall XMRV oder spezifische Antikörper gegen XMRV-Proteine nachgewiesen werden, obwohl nahezu identische, hochsensitive Verfahren verwendet wurden [14,15].…”